A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

A Phase 1, Evaluator-Blinded, Randomized, Vehicle Controlled Study To Evaluate The Phototoxic Potential Of Topically Applied Tazarotene Foam In Healthy Volunteers

Sponsors

Lead Sponsor: Stiefel, a GSK Company

Collaborator: GlaxoSmithKline

Source GlaxoSmithKline
Brief Summary

The purpose of this study is to evaluate the potential of Tazarotene Foam to induce a phototoxic reaction when exposed to UV and VIS light on skin of healthy volunteers.

Detailed Description

This is a Phase 1, single center, evaluator-blinded, randomized, vehicle controlled study to evaluate the potential of Tazarotene Foam 0.1% to induce a phototoxic reaction in healthy adult volunteers. Approximately 40 healthy, male and female, volunteer subjects aged 18 to 65 years will be enrolled.

Each subject will be exposed to three (3) sets of three (3) patches containing Tazarotene Foam, Vehicle Foam and a Blank Patch (no study product). Each patch set will be applied to randomized sites on the subject's back. Patch sets will be removed and evaluated after 24 hours of exposure. The exposed patch sites will then be irradiated (exposed to light) and evaluated at 1 hour post irradiation and at 24, 48, and 72 hours.

Overall Status Completed
Start Date April 1, 2010
Completion Date April 10, 2010
Primary Completion Date April 10, 2010
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Inflammatory skin responses Day 2-5 (24, 48, 72 hours following patch application).
Enrollment 38
Condition
Intervention

Intervention Type: Drug

Intervention Name: Tazarotene Foam without irradiation

Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Tazarotene Foam without irradiation

Intervention Type: Drug

Intervention Name: Tazarotene Foam with UVA and UVB irradiation

Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Tazarotene Foam with UVA and UVB irradiation

Intervention Type: Drug

Intervention Name: Tazarotene Foam with UVA, UVB, and visible light

Description: Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Tazarotene Foam with UVA , UVB, and visible light irradiation

Intervention Type: Drug

Intervention Name: Vehicle Foam without irradiation

Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Vehicle Foam without irradiation

Intervention Type: Drug

Intervention Name: Vehicle Foam with UVA and UVB irradiation

Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Vehicle Foam with UVA and UVB irradiation

Intervention Type: Drug

Intervention Name: Vehicle Foam with UVA and UVB and visible light irradiation

Description: Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: Vehicle Foam with UVA and UVB and visible light irradiation

Intervention Type: Drug

Intervention Name: No Treatment without irradiation

Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: No Treatment without irradiation

Intervention Type: Drug

Intervention Name: No Treatment with UVA and UVB irradiation

Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: No Treatment with UVA and UVB irradiation

Intervention Type: Drug

Intervention Name: No Treatment with UVA and UVB and visible light irradiation

Description: Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS). Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.

Arm Group Label: No Treatment with UVA and UVB and visible light irradiation

Eligibility

Criteria:

Inclusion Criteria:

- Capable of understanding and willing to provide signed and dated written voluntary informed consent and Health Information Portability and Accountability Act (HIPAA) authorization before any protocol-specific procedures are performed.

- Male or female aged 18 to 65 years, inclusive, at time of consent.

- Able and willing to complete the study and to comply with all study instructions.

- Possess Fitzpatrick skin types I (always burns easily; never tans), II (always burns easily; tans minimally), or III (burns moderately; tans gradually) that will not interfere with the evaluation of any skin responses (Fitzpatrick 1988). Determination of skin types will be based on sunburn and tanning histories, as well as subjects' opinions of their responses to the first 30 to 45 minutes of sun exposure.

- Male subjects and their partners must agree to use a medically acceptable method of contraception.

Additional criteria for women of childbearing potential, defined as one who is biologically capable of becoming pregnant, including perimenopausal women who are less than 2 years from their last menses:

- A regular menstrual cycle before study entry (as reported by the subject).

- Negative urine pregnancy test within 2 weeks of the first application of study product.

- Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception throughout the duration of the study. Acceptable contraceptive methods include the following:

- Hormonal contraception, including oral, injectable, or implantable methods started at least 2 months prior to screening. If hormonal contraception was started less than 2 months prior to screening, then a form of nonhormonal contraception should be added until the third continuous month of hormonal contraception has been completed.

- Two forms of reliable nonhormonal contraception, to include the use of either an intrauterine device plus a reliable barrier method or 2 reliable barrier methods. Reliable barrier methods include condoms or diaphragms. A cervical cap is also a reliable barrier method, provided that the female subject has never given birth vaginally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Subjects with surgical sterilization, including tubal sterilization or partner's vasectomy, must use a form of nonhormonal contraception. A barrier method or sterilization plus spermicide is acceptable.

Women who are not currently sexually active must agree to use a medically acceptable method of contraception should they become sexually active while participating in the study.

Exclusion Criteria:

- Female who is pregnant, trying to become pregnant, or breast feeding.

- Considered unable or unlikely to attend the necessary visits.

- History of known or suspected intolerance to tazarotene, any of the ingredients of the study products, the hypoallergenic tape, or the cotton patches.

- Participation in any patch test study within 4 weeks of Screening Visit 1.

- Inability to evaluate the skin in and around the potential patch test sites on the back due to sunburns, unevenness in skin tones, tattoos, scars, excessive hair, freckles, birthmarks, moles, or other skin damage or abnormality.

- Clinically significant skin diseases that may contraindicate participation or interfere with patch test site evaluations, including psoriasis, eczema, atopic dermatitis, acne, dysplastic nevi, or other skin pathologies, or a history of skin cancer.

- A history of severe reactions from exposure to sunlight, including previous experience with photoallergy, solar urticaria, polymorphous light eruptions, or other photo exacerbated systemic diseases.

- Any major illness within 4 weeks of Screening Visit 1.

- Considered immunocompromised.

- A clinically relevant history of or current evidence of abuse of alcohol or other drugs.

- Clinically relevant history or currently suffering from any disease or condition that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk. This may include respiratory (including chronic asthma requiring repetitive drug interventions), gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.

- Used photosensitizing medications (prescription, nonprescription, or herbal) or a known photosensitizing material within 2 weeks of Screening Visit 1.

- Received any investigational product or procedure within 4 weeks of Screening Visit 1 or is scheduled to receive an investigational product (other than the study product) or procedure during the study.

- Received allergy injections within 1 week of Screening Visit 1, or expects to receive allergy injections during study participation.

- Received immunizations within 4 weeks of Screening Visit 1.

- Used systemic or topical corticosteroids or other immunosuppressive medications within 4 weeks of Screening Visit 1.

- Used topical medications or other products (eg, self tanning products, waxing products, benzoyl peroxide, salicylic acid, or sulfur) in the areas of patch testing within 2 weeks of Screening Visit 1.

- Used antihistamines, selective leukotriene receptor antagonists (eg, montelukast sodium, zafirlukast), or mast cell stabilizers (eg, cromolyn sodium or nedocromil sodium) within 4 weeks of Screening Visit 1.

- Used nonsteroidal anti inflammatory medications within 2 weeks of Screening Visit 1.

- Currently using any medication that, in the opinion of the investigator, may affect the evaluation of the study product or place the subject at undue risk.

- Participated in a previous study of the same study product.

- Employee of the study center, contract research organization, or Stiefel who is involved in the study, or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee who is involved in the study.

Gender: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
GSK Clinical Trials Study Director GlaxoSmithKline
Location
Facility: HillTop Research Corporation
Location Countries

United States

Verification Date

June 2017

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 9
Arm Group

Label: Tazarotene Foam without irradiation

Type: Experimental

Description: Subjects will be exposed to Tazarotene Foam Patch without irradiation

Label: Tazarotene Foam with UVA and UVB irradiation

Type: Experimental

Description: Subjects will be exposed to Tazarotene Foam Patch with UVA and UVB irradiation

Label: Tazarotene Foam with UVA , UVB, and visible light irradiation

Type: Experimental

Description: Subjects will be exposed to Tazarotene Foam with UVA and UVB and visible light irradiation

Label: Vehicle Foam without irradiation

Type: Placebo Comparator

Description: Subjects will be exposed to Vehicle Foam Patch without irradiation

Label: Vehicle Foam with UVA and UVB irradiation

Type: Placebo Comparator

Description: Subjects will be exposed to Vehicle Foam Patch with UVA and UVB irradiation

Label: Vehicle Foam with UVA and UVB and visible light irradiation

Type: Placebo Comparator

Description: Subjects will be exposed to Vehicle Foam Patch with UVA and UVB and visible light irradiation

Label: No Treatment without irradiation

Type: Sham Comparator

Description: Subjects will be exposed to a Blank Patch without irradiation

Label: No Treatment with UVA and UVB irradiation

Type: Sham Comparator

Description: Subjects will be exposed to a Blank Patch with UVA and UVB irradiation

Label: No Treatment with UVA and UVB and visible light irradiation

Type: Sham Comparator

Description: Subjects will be exposed to a Blank Patch with UVA and UVB and visible light irradiation

Patient Data Yes
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Basic Science

Masking: Single (Outcomes Assessor)

Source: ClinicalTrials.gov